TERN Terns Pharmaceuticals, Inc. EV/EBITDA Multiple

Symbol and logo of brand Terns Pharmaceuticals Inc (TERN)

Terns Pharmaceuticals (TERN) possesses colossal growth potential driven by patents for high-margin liver medications. The company's EV/EBITDA chart illustrates the current enterprise value, where the current figure stands at 0.00. However, international gastrointestinal studies depend on global partnerships and component logistics. Meanwhile, the humanitarian status of the sector minimizes sanction risks, ensuring a neutral operating environment.

TERN (Terns Corp) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 05/16/2026

TERN (ternspharma.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Terns Pharmaceuticals Inc|TERN - Analyst Target Range
- market capitalization data:
Market Capitalization Terns Corp|TERN - Company Buyout Price
- issuer book value statistics:
Accounting Value per Share Terns Pharmaceuticals|TERN - Total Net Assets|Market Cap to Net Assets Ratio ternspharma.com|TERN - Aggregate Business Assets
- company liabilities and liquidity data:
Total Debt to Capital Terns Pharmaceuticals|TERN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Terns Pharmaceuticals, Inc.|TERN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Terns Corp|TERN - Company Long-Term Indebtedness|Company Short-Term Debt Terns Pharmaceuticals|Quick Liquidity Indicator ternspharma.com
- net income and valuation multiples indicators:
TERN - Final Profit|Expected Profit Terns Pharmaceuticals|TERN - Market Cap to Net Income|Forward P/E Multiple Terns Pharmaceuticals|TERN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Terns Corp|TERN - Operating profit EBITDA|Earnings per share for the last twelve months Terns Pharmaceuticals|TERN - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months ternspharma.com|TERN - Net earnings per share growth this year|Earnings growth forecast for next year Terns Pharmaceuticals
Summary company analysis:TERN (Terns Pharmaceuticals Inc)
Product sample of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals (TERN) strives for leadership in liver disease therapy, where clinical trial efficacy depends directly on flawless biosample logistics. By analyzing the company's EV/EBITDA multiple, an investor assesses the total enterprise value relative to operating profit, which allows for the determination of asset undervaluation and the sustainability of financial leverage within the long-term market consensus.

Competitor analysis for Terns Pharmaceuticals

EV/EBITDA Multiple PHAT (Phathom Corp)|Enterprise Value to EBITDA Multiple Ironwood Pharma|Curanex - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Immuron Limited IMRN|EVOK (Evoke Pharma) - Enterprise Value to EBITDA Ratio|ENTO: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio RDHL|PALI (palisadebio.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple JAGX|BIOR - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Morphic MORF